This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sprague, J. E. Articles by Anderson, C. J. Search for Related Content PubMed PubMed Citation Articles by Sprague, J. E. Articles by Anderson, C. J.

Preparation and Biological Evaluation of Copper-64–Labeled Tyr³-Octreotate Using a Cross-Bridged Macrocyclic Chelator

¹ Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri; and ² Department of Chemistry, University of New Hampshire, Durham, New Hampshire

Purpose: Somatostatin receptors (SSTr) are expressed on many neuroendocrine tumors, and several radiotracers have been developed for imaging these types of tumors. For this reason, peptide analogues of somatostatin have been well characterized. Copper-64 (t_1/2 = 12.7 hours), a positron emitter suitable for positron emission tomography (PET) imaging, was shown recently to have improved in vivo clearance properties when chelated by the cross-bridged tetraazamacrocycle 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo(6.6.2)hexadecane (CB-TE2A) compared with 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA).

Experimental Design: CB-TE2A and TETA were conjugated to the somatostatin analogue tyrosine-3-octreotate (Y3-TATE) for evaluation of CB-TE2A as a bifunctional chelator of ⁶⁴Cu. The in vitro affinity of each compound for SSTr was determined using a homologous competitive binding assay. In vivo characteristics of both radiolabeled compounds were examined in biodistribution and microPET studies of AR42J tumor-bearing rats.

Results: Cu-CB-TE2A-Y3-TATE (K_d = 1.7 nmol/L) and Cu-TETA-Y3-TATE (K_d = 0.7 nmol/L) showed similar affinities for AR42J derived SSTr. In biodistribution studies, nonspecific uptake in blood and liver was lower for ⁶⁴Cu-CB-TE2A-Y3-TATE. Differences increased with time such that, at 4 hours, blood uptake was 4.3-fold higher and liver uptake was 2.4-fold higher for ⁶⁴Cu-TETA-Y3-TATE than for ⁶⁴Cu-CB-TE2A-Y3-TATE. In addition, 4.4-times greater tumor uptake was detected with ⁶⁴Cu-CB-TE2A-Y3-TATE than with ⁶⁴Cu-TETA-Y3-TATE at 4 hours postinjection. MicroPET imaging yielded similar results.

Conclusions: CB-TE2A appears to be a superior in vivo bifunctional chelator of ⁶⁴Cu for use in molecular imaging by PET or targeted radiotherapy due to both improved nontarget organ clearance and higher target organ uptake of ⁶⁴Cu-CB-TE2A-Y3-TATE compared with ⁶⁴Cu-TETA-Y3-TATE.

This article has been cited by other articles:

				Z. Liu, Z.-B. Li, Q. Cao, S. Liu, F. Wang, and X. Chen Small-Animal PET of Tumors with 64Cu-Labeled RGD-Bombesin Heterodimer J. Nucl. Med., July 1, 2009; 50(7): 1168 - 1177. [Abstract] [Full Text] [PDF]

				A. L. Vavere, G. B. Biddlecombe, W. M. Spees, J. R. Garbow, D. Wijesinghe, O. A. Andreev, D. M. Engelman, Y. K. Reshetnyak, and J. S. Lewis A Novel Technology for the Imaging of Acidic Prostate Tumors by Positron Emission Tomography Cancer Res., May 15, 2009; 69(10): 4510 - 4516. [Abstract] [Full Text] [PDF]

				S. J. DeNardo, R. Liu, H. Albrecht, A. Natarajan, J. L. Sutcliffe, C. Anderson, L. Peng, R. Ferdani, S. R. Cherry, and K. S. Lam 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies J. Nucl. Med., April 1, 2009; 50(4): 625 - 634. [Abstract] [Full Text] [PDF]

				T. J. Wadas, M. Eiblmaier, A. Zheleznyak, C. D. Sherman, R. Ferdani, K. Liang, S. Achilefu, and C. J. Anderson Preparation and Biological Evaluation of 64Cu-CB-TE2A-sst2-ANT, a Somatostatin Antagonist for PET Imaging of Somatostatin Receptor-Positive Tumors J. Nucl. Med., November 1, 2008; 49(11): 1819 - 1827. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF]

				M. Ginj, H. Zhang, K.-P. Eisenwiener, D. Wild, S. Schulz, H. Rink, R. Cescato, J. C. Reubi, and H. R. Maecke New Pansomatostatin Ligands and Their Chelated Versions: Affinity Profile, Agonist Activity, Internalization, and Tumor Targeting Clin. Cancer Res., April 1, 2008; 14(7): 2019 - 2027. [Abstract] [Full Text] [PDF]

				J. C. Garrison, T. L. Rold, G. L. Sieckman, S. D. Figueroa, W. A. Volkert, S. S. Jurisson, and T. J. Hoffman In Vivo Evaluation and Small-Animal PET/CT of a Prostate Cancer Mouse Model Using 64Cu Bombesin Analogs: Side-by-Side Comparison of the CB-TE2A and DOTA Chelation Systems J. Nucl. Med., August 1, 2007; 48(8): 1327 - 1337. [Abstract] [Full Text] [PDF]

				M. Eiblmaier, R. Andrews, R. Laforest, B. E. Rogers, and C. J. Anderson Nuclear Uptake and Dosimetry of 64Cu-Labeled Chelator Somatostatin Conjugates in an SSTr2-Transfected Human Tumor Cell Line J. Nucl. Med., August 1, 2007; 48(8): 1390 - 1396. [Abstract] [Full Text] [PDF]

				A. F. Prasanphanich, P. K. Nanda, T. L. Rold, L. Ma, M. R. Lewis, J. C. Garrison, T. J. Hoffman, G. L. Sieckman, S. D. Figueroa, and C. J. Smith [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues PNAS, July 24, 2007; 104(30): 12462 - 12467. [Abstract] [Full Text] [PDF]

				J. E. Sprague, H. Kitaura, W. Zou, Y. Ye, S. Achilefu, K. N. Weilbaecher, S. L. Teitelbaum, and C. J. Anderson Noninvasive Imaging of Osteoclasts in Parathyroid Hormone-Induced Osteolysis Using a 64Cu-Labeled RGD Peptide J. Nucl. Med., February 1, 2007; 48(2): 311 - 318. [Abstract] [Full Text] [PDF]

				L. Wei, C. Butcher, Y. Miao, F. Gallazzi, T. P. Quinn, M. J. Welch, and J. S. Lewis Synthesis and Biologic Evaluation of 64Cu-Labeled Rhenium-Cyclized {alpha}-MSH Peptide Analog Using a Cross-Bridged Cyclam Chelator J. Nucl. Med., January 1, 2007; 48(1): 64 - 72. [Abstract] [Full Text] [PDF]

				D. Storch, M. Behe, M. A. Walter, J. Chen, P. Powell, R. Mikolajczak, and H. R. Macke Evaluation of [99mTc/EDDA/HYNIC0]Octreotide Derivatives Compared with [111In-DOTA0,Tyr3, Thr8]Octreotide and [111In-DTPA0]Octreotide: Does Tumor or Pancreas Uptake Correlate with the Rate of Internalization? J. Nucl. Med., September 1, 2005; 46(9): 1561 - 1569. [Abstract] [Full Text] [PDF]

				J. Grunberg, I. Novak-Hofer, M. Honer, K. Zimmermann, K. Knogler, P. Blauenstein, S. Ametamey, H. R. Maecke, and P. A. Schubiger In vivo Evaluation of 177Lu- and 67/64Cu-Labeled Recombinant Fragments of Antibody chCE7 for Radioimmunotherapy and PET Imaging of L1-CAM-Positive Tumors Clin. Cancer Res., July 15, 2005; 11(14): 5112 - 5120. [Abstract] [Full Text] [PDF]